Buergy D, Schneiberg V, Schaefer J, Welzel G, Trojan L, Bolenz C, Wenz F. Quality of life after low-dose rate-brachytherapy for prostate carcinoma - long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series. Health Qual Life Outcomes. 2018 Jan 22;16(1):21.
Bolenz C, Knauf D, John A, Erben P, Steidler A, Schneider SW, Günes C, Gorzelanny C. Decreased Invasion of Urothelial Carcinoma of the Bladder by Inhibition of Matrix-Metalloproteinase 7. Bladder Cancer. 2018 Jan 20;4(1):67-75.
Bolenz C, Schröppel B, Eisenhardt A, Schmitz-Dräger BJ, Grimm MO. The Investigation of Hematuria. Dtsch Arztebl Int. 2018 Nov 30;115(48):801-807. doi: 10.3238/arztebl.2018.0801.
Cebulla A, Bolenz C, Carrion DM, Bellut L. Urology training in Germany: international comparison of educational concepts and satisfaction. Urologe A. 2019 Jan 25. doi: 10.1007/s00120-019-0854-0.
Dogan S, Hennig M, Frank T, Struck JP, Cebulla A, Salem J, Borgmann H, Klatte T, Merseburger AS, Kramer M, Hofbauer SL. Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current Practice. Urol Int. 2018;101(1): 25-30
Ebert AK, Zwink N, Schwarzer N, Brunner L, Reutter H, Jenetzky E, Huber J, Ludwikowski B. Needs Assessment in Care of Adults With Anorectal Malformations and Exstrophy-Epispadias Complex in Germany. Front Pediatr. 2018 Dec 19;6:392. doi: 10.3389/fped.2018.00392.
Ebert AK, Zwink N, Jenetzky E, Stein R, Boemers TM, Lacher M, Fortmann C, Obermayr F, Fisch M, Mortazawi K, Schmiedeke E, Eisenschmidt V, Schäfer M, Hirsch K, Rösch WH, Reutter H. Association Between Exstrophy-epispadias Complex And Congenital Anomalies: A German Multicenter Study. Urology. 2019 Jan;123:210-220. doi: 10.1016/j.urology.2018.05.039.
Ebert AK, Zwink N, Reutter HM. Urology. 2019 Jan;123:219-220. doi: 10.1016/j.urology.2018.05.048.
Eckstein M, Wirtz RM, Gross-Weege M, Breyer J, Otto W, Stoehr R, Sikic D, Keck B, Eidt S, Burger M, Bolenz C, Nitschke K, Porubsky S, Hartmann A, Erben P. mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants. Int J Mol Sci. 2018 Oct 30;19(11).
Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P. A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget. 2018 Feb 19;9(19):15001-15014.
Eckstein M: Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
Erben P, Sikic D, Wirtz RM, Martini T, Weis CA, Breyer J, Otto W, Keck B, Hartmann A, Bolenz C; BRIDGE Consortium e.V. Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder. Virchows Arch. 2019 Feb;474(2):209-217. doi: 10.1007/s00428-018-2496-9.
Günes C, Wezel F, Southgate J, Bolenz C. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis. Nat Rev Urol. 2018 Jun;15(6):386-393. doi: 10.1038/s41585-018-0001-5. Review.
Günes C, Avila AI, Rudolph KL. Telomeres in cancer. Differentiation. 2018 Jan - Feb;99:41-50. doi: 10.1016/j.diff.2017.12.004.
Hausmann D, Aksöz N, von Hardenberg J, Martini T, Westhoff N, Buettner S, Schoenberg SO, Riffel P. Prostate cancer detection among readers with different degree of experience using ultra-high b-value diffusion-weighted Imaging: Is a non-contrast protocol sufficient to detect significant cancer? Eur Radiol. 2018 Feb;28(2):869-876. doi: 10.1007/s00330-017-5004-8. Epub 2017 Aug 10.
Hautmann R, Bolenz C. Declining Use of Orthotopic Reconstruction for Bladder Cancer. Ann Surg Oncol. 2018 Nov;25(12):3421-3422. doi: 10.1245/s10434-018-6570-y.
Hupe MC, Hoda MR, Zengerling F, Perner S, Merseburger AS, Cronauer MV. The BET-inhibitor PFI-1 diminishes AR/AR-V7 signaling in prostate cancer cells. World J Urol. 2018 Jun 22. doi: 10.1007/s00345-018-2382-8. [Epub ahead of print]
Hustler A, Eardley I, Hinley J, Pearson J, Wezel F, Radvanyi F, Baker SC, Southgate J. Differential transcription factor expression by human epithelial cells of buccal and urothelial derivation. Exp Cell Res. 2018 Aug 15;369(2):284-294. doi: 10.1016/j.yexcr.2018.05.031.
John, A., Baumgart, A.,john a Worst, T., & Heinzelbecker, J. (2018). Economy of Standards: European Association of Urology Guideline Changes Influence Treatment Costs in Stage I Testicular Cancer Patients. Urologia internationalis, 100(3), 279-287.
John A, Gorzelanny C, Bauer AT, Schneider SW, Bolenz C. Role of the Coagulation System in Genitourinary Cancers. Clin Genitourin Cancer. 2017 Jul 26. pii: S1558-7673(17)30210-0. doi: 10.1016/j.clgc.2017.07.013.
Klein JT, Berger F, Linzenbold W, Jäger L, Enderle MD, Bösmüller H, Mundhenk J, Schwentner C, Bolenz C. Cryobiopsy in the Upper Urinary Tract: Preclinical Evaluation of a Novel Device. Urology. 2019 Jan;123:273-279. doi: 10.1016/j.urology.2018.10.003.
Kriegmair MC, Honeck P, Theuring M, Bolenz C, Ritter M. Wide-field autofluorescence-guided TUR-B for the detection of bladder cancer: a pilot study. World J Urol. 2018 May;36(5):745-751.
Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, Hartmann A, Bolenz C, Erben P. Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer. Transl Oncol. 2018 Apr;11(2):467-476.
Martini T, Heinkele J, Mayr R, Weis CA, Wezel F, Wahby S, Eckstein M, Schnöller T, Breyer J, Wirtz R, Ritter M, Bolenz C, Erben P. Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy. Urol Oncol. 2018 Dec;36(12):530.e19-530.e27. doi: 10.1016/j.urolonc.2018.09.003.
Martinschek A, Welzel G, Ritter M, Heinrich E, Bolenz C, Trojan L. The concentration of console surgeons: prospective evaluation of the loss of attention in robotic-assisted procedures. J Robot Surg. 2018 Dec;12(4):673-678.
Mayr R, Gierth M, Zeman F, Reiffen M, Seeger P, Wezel F, Pycha A, Comploj E, Bonatti M, Ritter M, van Rhijn BWG, Burger M, Bolenz C, Fritsche HM, Martini T. Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer. J Cachexia Sarcopenia Muscle. 2018 Jun;9(3):505-513.
Necknig U, Leyh H, Hauenstein K, Zwink N, Becker T, Ebert AK.[Pilot study on drinking and voiding management in child day-care facilities in the district of Garmisch-Partenkirchen]. Urologe A. 2018 Dec 12. doi: 10.1007/s00120-018-0825-x.
Retz M, Bedke J, Bögemann M, Grimm MO, Zimmermann U, Müller L, Leiber C, Teber D, Wirth M, Bolenz C, van Alphen R, De Santis M, Beeker A, Lehmann J, Indorf M, Frank M, Bokemeyer C, Gschwend JE. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). Eur J Cancer. 2019 Jan;107:37-45. doi: 10.1016/j.ejca.2018.11.001.
Rinaldetti S, Rempel E, Worst TS, Eckstein M, Steidler A, Weiss CA, Bolenz C, Hartmann A, Erben P. Subclassification, survival prediction and drug target analyses of chemotherapy-naïve muscle-invasive bladder cancer with a molecular screening. Oncotarget. 2018 May 25;9(40):25935-25945.
Salem J, Paffenholz P, Bolenz C, von Brandenstein M, Cebulla A, Haferkamp A, Kuru T, Lee CT, Pfister D, Tsaur I, Borgmann H, Heidenreich A. Websites on Bladder Cancer: an Appropriate Source of Patient Information? J Cancer Educ. 2018 Jan 8.
Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. Urol Oncol. 2018 Jul;36(7):343.e1-343.e8.
Traceviciute J, Zwink N, Jenetzky E, Reutter H, Hirsch K, Stein R, Rösch WH, Ebert AK. Sexual Function and Quality of Life in Adult Male Individuals with Exstrophy-Epispadias Complex-a Survey of the German CURE-Network. Urology. 2018 Feb;112:215-221. doi: 10.1016/j.urology.2017.08.063.
Vetterlein MW, Gild P, Kluth LA, Seisen T, Gierth M, Fritsche HM, Burger M, Protzel C, Hakenberg OW, von Landenberg N, Roghmann F, Noldus J, Nuhn P, Pycha A, Rink M, Chun FK, May M, Fisch M, Aziz A; PROMETRICS 2011 Study Group. Peri-operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity score-weighted European multicentre study. BJU Int. 2018 Jan;121(1):101-110.
von Hardenberg J, Worst TS, Westhoff N, Erben P, Fuxius S, Müller M, Bolenz C, Weiss C, Heinrich E. Cell-Free DNA and Neuromediators in Detecting Aggressive Variant Prostate Cancer. Oncol Res Treat. 2018;41(10):627-633. doi: 10.1159/000490618.
von Hardenberg J, Westhoff N, Baumunk D, Hausmann D, Martini T, Marx A, Porubsky S, Schostak M, Michel MS, Ritter M. Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation. Urol Oncol. 2018 Sep;36(9):401.e1-401.e9. doi: 10.1016/j.urolonc.2018.05.022.
Westhoff N, Siegel F, Peter C, Hetjens S, Porubsky S, Martini T, von Hardenberg J, Michel MS, Budjan J, Ritter M. Defining the target prior to prostate fusion biopsy: the effect of MRI reporting on cancer detection. World J Urol. 2018 Jul 2. doi: 10.1007/s00345-018-2400-x. [Epub ahead of print]
Wezel F, Erben P, Gaiser T, Budjan J, von Hardenberg J, Michel MS, Bolenz C. Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine. Urol Int. 2018;100(1):122-125. doi: 10.1159/000443280.
Worst TS, Weis CA, Stöhr R, Bertz S, Eckstein M, Otto W, Breyer J, Hartmann A, Bolenz C, Wirtz RM, Erben P. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. Sci Rep. 2018 Sep 26;8(1):14383. doi: 10.1038/s41598-018-32569-x.
Zengerling F. Phytotherapy for benign prostatic hyperplasia. Urologe A. 2018 Jun 6. doi: 10.1007/s00120-018-0687-2.
Zengerling F, Kunath F, Jensen K, Ruf C, Schmidt S, Spek A. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance-A systematic review. Urol Oncol. 2018 Oct;36(10):448-458. doi: 10.1016/j.urolonc.2017.06.047.
Zuiverloon TCM, van Kessel KEM, Bivalacqua TJ, Boormans JL, Ecke TH, Grivas PD, Kiltie AE, Liedberg F, Necchi A, van Rhijn BW, Roghmann F, Sanchez-Carbayo M, Schmitz-Dräger BJ, Wezel F, Kamat AM. Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network. Urol Oncol. 2018 Sep;36(9):423-431. doi: 10.1016/j.urolonc.2018.01.014. Review.